Aripiprazole is an atypical antipsychotic that is a partial agonist at the D2 and 5HT1a receptors and an antagonist at 5HT2a receptors. Despite previous hypotheses that it would be less likely to cause movement disorders, recent reports suggest it actually may be more likely to cause movement disorders than other atypical antipsychotics. This case series illustrates the variety of movement diso...

Aripiprazole is reported to be a good clinical safety profile antipsychotic. However, recent data suggest that the risk of tardive dyskinesia could be higher than initially thought. We report the case of aripiprazole-induced tardive dyskinesia with dramatic evolution in a patient with several risk factors, including older age and exposure to antipsychotic over a period longer than six months. T...

Secondary: The secondary objectives of this study were to compare the efficacy profiles of aripiprazole versus olanzapine based upon the results of efficacy scales (PANSS, Clinical Global Impression [CGI], and Montgomery-Asberg Depression Rating Scale [MADRS]), and to compare the safety and tolerability of aripiprazole versus olanzapine, and the response rate and discontinuation rate in patient...

A simple, accurate and economic spectrophotometric method for the determination of aripiprazole in tablet formulation is proposed. In the present method acidic solution of the aripiprazole formed colored ion-association complexes with bromocresol green, soluble in chloroform. Yellowish orange chromogen showed λ(max) at 414 nm and obeyed Beer's law in the concentration range of 10-60 μg/ml. Stat...

OBJECTIVE To evaluate the cost-effectiveness of aripiprazole and olanzapine in patients with schizophrenia. METHODS Data from a double-blind, randomized study demonstrating the efficacy of aripiprazole and olanzapine were used to observe new incidence of metabolic syndrome (26-week therapy) and to model the risk of developing diabetes over 5 years of therapy. Cumulative incidence of metabolic...

BACKGROUND We conducted a systematic review and meta-analysis of randomized controlled trials comparing aripiprazole with pooled antipsychotics in Japanese patients with schizophrenia. METHODS We performed a literature search of data published in PubMed(®), the Cochrane Library database, the Japan Medical Abstracts Society, and PsycINFO(®) up to January 5, 2014. The odds ratio (OR), number-ne...


 For antipsychotic-related sexual dysfunction, 1 guideline recommends switching to aripiprazole or another non-hyperprolactinemic antipsychotic as the first option. Alternatively, adjunctive treatment with aripiprazole, antipsychotics that have less impact on function. Another adding estrogen testosterone medication assist dysfunction in women.
 antidepressant-related agomelatine a n...

BACKGROUND Second-generation antipsychotics, approved for the treatment of mania, are associated with adverse effects such as weight gain and metabolic disorders. Aripiprazole, a recently introduced second-generation antipsychotic, are thought to account for its low propensity for weight gain, metabolic disturbances and sedation. The purpose of this study was to investigate the effect of risper...

OBJECTIVE To determine the feasibility and safety of aripiprazole augmentation for incomplete response to sequential selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) pharmacotherapy in late-life depression. METHOD This study was a 12-week, open-label pilot study of 24 patients (recruited from June 1, 2006, to June 1, 2007) aged 65 years and ...

BACKGROUND Autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are frequently overlapping neurodevelopmental disorders. Individuals in whom the disorders are comorbid show more severe impairment because of deficits in the processing of social situations, adaptive functioning, and executive control than individuals with either disorder alone. OBJECTIVE This open-...